Beigene (ONC) Competitors

GSK (NYSE:GSK) and Beigene (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.

Do insiders and institutionals have more ownership in GSK or ONC?

15.7% of GSK shares are held by institutional investors. Comparatively, 48.5% of Beigene shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 6.6% of Beigene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate GSK or ONC?

GSK presently has a consensus target price of $40.58, indicating a potential upside of 3.95%. Beigene has a consensus target price of $318.88, indicating a potential upside of 24.67%. Given Beigene's stronger consensus rating and higher possible upside, analysts clearly believe Beigene is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.42
Beigene	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is GSK or ONC more profitable?

GSK has a net margin of 8.13% compared to Beigene's net margin of -25.94%. GSK's return on equity of 48.59% beat Beigene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	8.13%	48.59%	11.11%
Beigene	-25.94%	-25.12%	-14.95%

Does the MarketBeat Community favor GSK or ONC?

GSK received 815 more outperform votes than Beigene when rated by MarketBeat users. However, 75.00% of users gave Beigene an outperform vote while only 57.10% of users gave GSK an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 824 57.10%	Underperform Votes 619 42.90%
Beigene	Outperform Votes 9 75.00%	Underperform Votes 3 25.00%

Which has stronger earnings & valuation, GSK or ONC?

GSK has higher revenue and earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$31.53B	2.55	$3.29B	$1.94	20.12
Beigene	$3.81B	6.64	-$881.71M	-$6.14	-41.66

Does the media prefer GSK or ONC?

In the previous week, GSK had 20 more articles in the media than Beigene. MarketBeat recorded 36 mentions for GSK and 16 mentions for Beigene. GSK's average media sentiment score of 0.86 beat Beigene's score of -0.18 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	13 Very Positive mention(s)	5 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Beigene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, GSK or ONC?

GSK has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.

Summary

GSK beats Beigene on 13 of the 19 factors compared between the two stocks.